✨ Free AI Report
Nuclera: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Nuclera
Company Research

Nuclera: Business Overview, Financials & Competitive Analysis

Nuclera is a biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System. The platform delivers assay-ready proteins, includ...

Analyst-debate audio for Nuclera

AskCyborg analysts argue the bull and bear cases for Nuclera across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Well-capitalized platform company solving genuine biotech bottleneck with expanding AI-integrated capabilities and growing...

Read the full analyst-debate transcript →
Industry Biotechnology
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Nuclera Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Nuclera Overview

Pro stress-test →

Nuclera is a biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System. The platform delivers assay-ready proteins, including challenging membrane proteins, in as little as 48 hours through multiplex screening of constructs, tags, and conditions, addressing a critical bottleneck in biologics research and drug development.

Strategic Profile

Pro stress-test →

Nuclera is moving into AI-enabled protein engineering, addressing a critical industry need for scalable, standardized, and high-quality datasets that can be used to power next-generation AI models. The company has secured significant funding to enable broad commercialization, expanded their leadership team to support scale-up, and continues to drive advancements in drug discovery, proteomics, and experimental automation.

Competitive Landscape

Pro stress-test →

Nuclera competes in the protein engineering and synthetic biology tools space against academic platforms and automation vendors. Direct competitors include benchtop and cloud-based protein design/expression platforms serving the same pharma R&D and academic research customer base. The company's differentiation lies in speed-to-protein (48 hours), multiplex screening, and integration with AI/ML datasets for next-generation therapeutics.

Industry Context

Nuclera operates in Biotechnology.

Key facts

Founded: 2016 · Headquarters: Cambridge, UK and Boston, MA · Employees: Not available · Revenue: Not publicly available

What the analysts stress-tested

The top findings that survived the multi-agent debate for Nuclera.

  • In January 2026, Nuclera extended Series C funding to $87M total, led by Elevage Medical Technologies and Jonathan Milner, enabling expanded antibody engineering and AI integration—critical for capturing the emerging AI-biologics datasets market.
  • Nuclera's benchtop platform uses cell-free synthesis, digital microfluidics, and software automation to enable miniaturized protein prototyping for challenging targets like membrane proteins, creating sticky customer relationships in academic and industrial drug discovery.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Series C extension to $87M total for antibody engineering and AI-enabled protein engineering capabilities
  • 2024Ranked among fastest-growing UK/Ireland startups
  • +1 moreTrack every material event for Nuclera as it happens. Explore monitoring →
Get alerted when Nuclera has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SynthegoCell-free protein synthesis and CRISPR gene editing platform→Intrinsic TherapeuticsAI-driven protein design platform for drug discovery→AbsciCloud-based AI protein design and optimization platform→HelixworksBenchtop automation platform for protein engineering and expression→

Compare Nuclera with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Nuclera operates in Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology research →
NEW · MCP server

Ask your AI assistant about Nuclera

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Nuclera and its top competitor on Cyborg Score”
“What did Nuclera do this quarter?”
“Is Nuclera a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Nuclera do?+
Nuclera is a biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System. The platform delivers assay-ready proteins, includ...
What is Nuclera's Cyborg Score?+
Nuclera has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Nuclera's main competitors?+
Named competitors include Synthego, Intrinsic Therapeutics, Absci, Helixworks. The full competitive landscape is in the AskCyborg report.
How can I get the full Nuclera research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Nuclera research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Nuclera over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend Biotech6Absci CorporationTop companies in Biotechnology by Cyborg Score